Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 7:54 PM ET

Biotechnology

Company Overview of Garnet Biotherapeutics, Inc.

Executive Profile

Geraldine A. Henwood Ph.D.

Chief Executive Officer, President and Director, Recro Pharma, Inc.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 6 different industries.

See Board Relationships
62$1,507,860
As of Fiscal Year 2014

Background

Dr. Geraldine A. Henwood, also known as Gerri, Ph.D. has been the Chief Development Officer of Iomab-B at Actinium Pharmaceuticals, Inc. since September 2012. Dr. Henwood has been the Chief Executive Officer of Garnet Biotherapeutics, Inc. since November 2008. Dr. Henwood has been the Chief Executive Officer and President of RECRO Pharma, Inc. since 2008. She is a Venture Partner at SCP Vitalife. She is the Founder/President of Malvern Consulting Group. Dr. Henwood has ...

Corporate Headquarters

490 Lapp Road
Malvern, Pennsylvania 19355

United States

Phone: 484-395-2440
Fax: 484-395-2401

Board Members Memberships

Director
1992-N/A
Former Chief Executive Officer, President and Executive Director
1999-N/A
Founder
2004-2013
Former Director and Chairman of Compensation Committee
2008-Present
Chief Executive Officer and Director
2008-Present
Chief Executive Officer, President and Director
2011-2015
Former Director and Member of Compensation Committee

Education

BS
Neumann University

Other Affiliations

Annual Compensation

Salary$285,375
Bonus$205,000
Total Annual Compensation$490,375

Stocks Options

All Other Compensation$23,645
Exercisable Options$19,539
Unexercisable Options$203,961
Total Number of Options$347,000

Total Compensation

Total Annual Cash Compensation$514,020
Total Short Term Compensation$490,375
Other Long Term Compensation$23,645
Total Calculated Compensation$1,507,860
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Garnet Biotherapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.